Trek Therapeutics™: A pharmaceutical company on the outside, a benefit corporation on the inside: Trek Therapeutics, PBC (TrekTx) is a pharmaceutical company structured as a benefit corporation and designed to create a better balance between profitability and affordability. The founders of Trek Therapeutics have deep virology, clinical and CMC expertise and experience from participating in the development of seven approved antiviral drugs, including a HBV polymerase (entecavir), HIV protease inhibitors (agenerase, fosamprenavir), HCV polymerase inhibitor (sofosbuvir), HCV NS5A inhibitor (daclatasvir), and HCV protease inhibitors (boceprevir, telaprevir), in addition to drug approvals outside of virology.

Our vision is to develop novel and affordable therapeutic regimens for the treatment of communicable diseases. TrekTx’s first undertaking will be for treatment of hepatitis C virus. We will apply our learning from the HCV program to other therapeutic agents in infectious disease areas where we can leverage our expertise to create socially-responsible and profitable drugs for patients across the economic spectrum.

Our mission is to travel the world to treat infectious diseases with innovative therapeutics at affordable prices.

Our strategy for world-wide elimination of HCV infection: Infection with HCV is a serious disease that is associated with progression to advanced liver disease, liver cancer, and death. In the US, more patients receive a liver transplant for advanced liver disease due to chronic HCV-infection than any other disease. HCV infection is a world-wide phenomenon, affecting the entire economic spectrum. Although a cure to eliminate the virus has been developed, the expense of this treatment means that it is unavailable to most patients in both the developed and developing worlds. Trek Therapeutics will create a new HCV combination regimen, manufacture it, and market it in high-income settings at quasi-generic pricing. In other economic settings, Trek Therapeutics will market the drug via a tiered pricing structure that may include pricing that is slightly above the cost of goods (COG) in low income areas.